⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GOSS News
Gossamer Bio, Inc. Common Stock
GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit - Contact The Gross Law Firm
prnewswire.com
GOSS
GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
prnewswire.com
GOSS
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Gossamer Bio, Inc. to Contact the Firm Today!
accessnewswire.com
GOSS
Pomerantz LLP Notifies Investors of Class Action Filing Against Gossamer Bio, Inc. – GOSS
accessnewswire.com
GOSS
Pulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsight
prnewswire.com
UTHR
LQDA
GOSS
INSM
JNJ
MRK
GOSS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 Ready to Announce with Confidence?
newsfilecorp.com
GOSS
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com
GOSS
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS
globenewswire.com
GOSS
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
globenewswire.com
GOSS
Pomerantz LLP Notifies Investors of Class Action Lawsuit Against Gossamer Bio, Inc. – GOSS
accessnewswire.com
GOSS